16:27:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Vistin Pharma är ett norskt läkemedelsbolag. Bolaget bedriver forskning och utveckling samt vidare produktion av farmaceutiska substanser (API), främst substanserna metformin, kodein fosfat och folkodin. Substanserna används huvudsakligen vid behandling av diabetes. Idag innehas verksamhet på global nivå, med störst närvaro på den nordiska marknaden. Vistin Pharma grundades under 2015 och har sitt huvudkontor i Oslo.

Kalender

2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning VISTN 0.50 NOK
2021-05-20 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-10-30 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-06-24 Extra Bolagsstämma 2020
2020-05-20 Ordinarie utdelning VISTN 1.00 NOK
2020-05-19 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning VISTN 0.00 NOK
2019-05-22 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-19 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning VISTN 1.00 NOK
2018-05-08 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-03 Bonusutdelning VISTN 7
2017-11-02 Extra Bolagsstämma 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning VISTN 1.00 NOK
2017-05-24 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-10-31 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-05-25 Ordinarie utdelning VISTN 0.60 NOK
2016-05-24 Årsstämma 2016
2016-04-28 Kvartalsrapport 2016-Q1
2016-02-23 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2020-08-28 07:30:00

Oslo, Norway, 28 August 2020

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the second quarter and first half of 2020, with a 20% increase in revenue and EBITDA of MNOK 20.9 for the pharmaceutical business in Q2 – highest revenue and EBITDA ever in a quarter. For first half 2020 revenue increased by 30% and EBITDA by 200% versus first half 2019.

The revenues for the second quarter of 2020 ended at MNOK 73 (Q2’19: MNOK 61.1). For first half of 2020 the revenue was MNOK 134.4, compared to MNOK 103.3 in first half of 2019, a growth of 30%.

Second quarter EBITDA for pharmaceuticals was MNOK 20.9 (Q1’19: MNOK13.3), and a first half 2020 EBITDA of MNOK 35.1, compared to MNOK 11.7 in first half of 2019.

The net profit for the group ended at MNOK 20.7 (Q2’19: MNOK 0.4) for the second quarter of 2020. For first half 2020 the net loss was MNOK 110.1, compared to profit of MNOK 2.4 in first half of 2019, driven by the loss of closing the oil derivative portfolio in March.

Vistin Pharma had cash of MNOK 109 (Q2’19 MNOK: 290.7) as of 30 June 2020, and a strong balance sheet with an equity ratio of 83%. Dividend of NOK 1 per share was paid to shareholders in June.

The second quarter conference call, which will be held today, 28 August, at 8.30am (CEST) and will be available via web and audio through the following access points:

Telephone conference:
Confirmation Code:........ 9358318
International Dial-In:........ +44 (0) 2071 928338
Norway, Oslo:................ +47 21563015
United States, New York: +1 6467413167

Webcast:
https://edge.media-server.com/mmc/p/b48bigg6

The conference call will be held in Norwegian.
       

Please find the Q2 and first half 2020 report and presentation enclosed. The report will also be made available on www.vistin.com.

*****

For further information, please contact:

Kjell-Erik Nordby
CEO
+47 91 36 42 80
kjell-erik.nordby@vistin.com

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.